LIANOS ACKERT

Opportunities

COPD:

• no approved biologc options
• early diagnosis is important

IPF

2 competitors

• early diagnosos
• tolerability
• trail enrollment is quite slow

---

SPAEKER 2

COPD | IPF Fipaxalparant (LPAR1 SM) : mice protected against IPFß

JAG-1 pathway

---

precision medicine: benefit vs toxicity Exposome | generalized biomarkers

ASTA

population data --> deCODE project

ASTHMA drug

• Cys273Tyr pvalue e-13
• Large data sources and genomics

Ian

• Primary care makes outcomes better as shown in heart disease
• Fire alarm: get before damage
• peresymptomatic damage (damage befor symptoms manifest)
• obvious comorbidities cannot distinguish outcomes very well
• Have to move away from damage based constructs of teh disease
• prognostic and predictive biomarkers

Toby

• quality of life prediction
• Prediction with antifibrotic adverse effect metric (everything goes bad)